Conversations

Conversations: Fireside Video Chats

The “Conversations” video series will feature virtual fireside chats with neuroscience experts who will discuss advances in the research and treatment of Alzheimer’s disease, dementia with Lewy bodies (DLB), and other age-related neurodegenerative conditions.

Please note, our podcast series does not constitute the practice of medical advice, diagnosis or treatment. Always talk to your health care provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately.

Episode 7: Quantitative EEG: Effects of CT1812 on Measures of Synaptic Function in Alzheimer’s Disease

Featuring:
Anthony Caggiano, M.D., Ph.D. (moderator)
Cognition Therapeutics
Chief Medical Officer
Willem de Haan, M.D., Ph.D.
Alzheimer Center at Amsterdam University Medical Center
Neurologist and Senior Researcher
Philip Scheltens, M.D.
EQT Life Sciences
Partner and Head of Dementia Fund
Former Director of the Alzheimer Center at Amsterdam University Medical Center
Index:
0:00 Introduction
0:44 Rationale for the SEQUEL Study Design
2:10 EEG in neurodegenerative diseases
4:33 Findings from SEQUEL
9:52 Key Takeaways

Episode 6: Geographic Atrophy: New Strategies to Protect the Retina

Featuring:
Anthony Caggiano, M.D., Ph.D.
Cognition Therapeutics
Chief Medical Officer
C. Gustavo De Moraes, M.D., Ph.D.
moderator
Columbia University and Ora (CRO)
Associate Professor of Clinical Ophthalmology
Chief Medical Officer
Jeffrey S. Heier, M.D.
Ophthalmic Consultants of Boston
Director of the Vitreoretinal Service & Retina Research
Peter K. Kaiser, M.D.
Cleveland Clinic Lerner College of Medicine
Chaney Family Endowed Chair in Ophthalmology Research
and Professor of Ophthalmology
Index:
0:00 Introduction
01:53 Advances in Understanding of Geographic atrophy
06:05 Role of Complement in dry AMD
10:50 Evidence for sigma-2 modulation
19:29 The MAGNIFY Trial

Episode 5: Exploring the Effects of CT1812 on Alzheimer’s Disease Processes: Proteomics and Pathways of Neurodegeneration​

Featuring:
Mary Hamby, Ph.D.
Cognition Therapeutics
Vice President of Research
Charlotte Teunissen, Ph.D.
moderator
Amsterdam University Medical Center
Professor of Clinical Neurochemistry
Nicholas Seyfried, Ph.D.
Emory University School of Medicine
Professor of Biochemistry and Neurology
Director of the Emory Integrated Proteomics Core
Henrik Zetterberg, MD, Ph.D.
Gothenburg University
Professor of Neuroscience
Group Leader of the UK Dementia Research Institute
Index:
0:00 Introduction
01:53 Utility of Proteomic Analysis in Alzheimer’s
03:20 Review of Proteomics Findings from AD/PD 2023
08:36 Key Learnings
Scroll to Top

Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. 

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.